Genome-Wide Association Studies (GWAS) of Angiotensinogen Levels in the Multi-Ethnic Study of Atherosclerosis (MESA)
Abstract Body (Do not enter title and authors here): Background: The renin angiotensin aldosterone system (RAAS) is crucial for circulatory homeostasis and multiple cardiovascular diseases. Despite research on key RAAS components, resulting in multiple therapeutics, the role of angiotensinogen, the sole substrate, remains less understood. We sought to elucidate the relationship between circulating angiotensinogen levels and single nucleotide polymorphisms (SNPs) in a multi-ethnic cohort study.
Methods: Genome-wide association analyses of plasma angiotensinogen levels were conducted in 4,899 MESA participants (self-identified as White, n=1,868; Hispanic, n=1,115; Black, n=1,283; and Chinese, n=633). Plasma angiotensinogen levels were measured at the baseline using an enzyme-linked immunoassay. Linear models were adjusted for age, sex, comorbidities, and sex hormones, along with top principal components to account for population structure. Furthermore, we conducted conditional analysis identifying SNPs meeting genome-wide significance for population-specific associations conditioned on the lead SNP in each race/ethnicity.
Results: We identified 115 SNPs associated with angiotensinogen levels (p< 5×10−8), including the lead SNP rs4762 (Thr174Met) in exon 2 (β=-0.159, p=1.51E-100) and SNP rs5050 (A-20C) in the promoter region (β=-0.109, p=2.26E-69) within the AGT gene. Strong Linkage Disequilibrium [LD (r2>0.8)] was observed between rs4762 and rs35837081 for White, Black, and Hispanic ethnicities. Conversely, this level of LD was noted between rs4762 and rs3789657 specifically within Chinese. The LD between rs4762 and rs5050 was higher for White (r2=0.65), followed by Chinese (r2=0.56), Hispanic (r2=0.55), and Black (r2=0.29). Conditioned on rs4762 in the White population, we identified four secondary signals associated with angiotensinogen including rs2493151 (β=0.053, p=4.08E-9), implicated in transcription factor binding. Measured angiotensinogen levels were 9.7%, 12.8%, and 17.3% lower in Black, Hispanic, and Chinese, respectively, compared to White participants.
Conclusions: These findings extend angiotensinogen research, highlighting the SNPs rs4762 and rs5050 as the key variants associated with angiotensinogen levels, both previously linked to hypertension.
Lidani, Karita
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Guo, Xiuqing
( The Lundquist Institute
, Torrance
, California
, United States
)
Rotter, Jerome
( The Lundquist Institute
, Torrance
, California
, United States
)
Tsimikas, Sotirios
( University of California San Diego
, La Jolla
, California
, United States
)
Trainor, Patrick
( New Mexico State University
, Las Cruces
, New Mexico
, United States
)
Defilippis, Andrew
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Tomar, Shubham
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Mousavi, Hossein
( New Mexico State University
, Las Cruces
, New Mexico
, United States
)
Buscaglia, Robert
( Northern Arizona University
, Flagstaff
, Arizona
, United States
)
Landry, Alexander
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Michael, Kirolos
( Meharry Medical College
, Nashville
, Tennessee
, United States
)
Dupuis, Leonie
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Michos, Erin
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Morgan, Erin
( Ionis Pharmaceuticals Inc.
, Carlsbad
, California
, United States
)
Author Disclosures:
Karita Lidani:DO NOT have relevant financial relationships
| Xiuqing Guo:DO NOT have relevant financial relationships
| Jerome Rotter:DO NOT have relevant financial relationships
| Sotirios Tsimikas:DO have relevant financial relationships
;
Research Funding (PI or named investigator):NIH:Active (exists now)
; Consultant:regeneron:Past (completed)
; Employee:Ionis:Active (exists now)
; Ownership Interest:Kleanthi:Active (exists now)
; Ownership Interest:oxitope:Active (exists now)
; Consultant:Novartis:Active (exists now)
| Patrick Trainor:DO NOT have relevant financial relationships
| Andrew DeFilippis:DO have relevant financial relationships
;
Researcher:National Institutes of Health:Active (exists now)
; Consultant:Velakor:Past (completed)
; Researcher:Ionis:Past (completed)
| Shubham Tomar:DO NOT have relevant financial relationships
| Hossein Mousavi:DO NOT have relevant financial relationships
| Robert Buscaglia:DO NOT have relevant financial relationships
| Alexander Landry:DO NOT have relevant financial relationships
| Kirolos Michael:DO NOT have relevant financial relationships
| Leonie Dupuis:No Answer
| Erin Michos:DO have relevant financial relationships
;
Consultant:Novo Nordisk:Active (exists now)
; Consultant:Bayer:Active (exists now)
; Consultant:Zoll:Past (completed)
; Consultant:Arrowhead:Active (exists now)
; Consultant:Novartis:Past (completed)
; Consultant:Amgen:Past (completed)
; Consultant:AstraZeneca:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:Edwards Lifescience:Active (exists now)
; Consultant:Merck:Active (exists now)
; Consultant:Eli Lilly:Active (exists now)
; Consultant:New Amsterdam:Active (exists now)
; Consultant:Esperion:Active (exists now)
; Consultant:Boehringer Ingelheim:Active (exists now)
| Erin Morgan:DO have relevant financial relationships
;
Employee:Ionis:Active (exists now)